Abstract
ObjectivesTo evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).MethodsA total of 159 patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have